{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T20:21:29Z","timestamp":1787602889808,"version":"build-2736575974"},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1762","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>The FDA has approved the over-the-counter (OTC) sale of Rextovy (Amphastar), a nasal spray formulation of the opioid antagonist naloxone, for emergency treatment of opioid overdose.1 Other naloxone nasal sprays (Narcan, and generics; RiVive) are also available OTC (see Table 1).<\/jats:p>","DOI":"10.58347\/tml.2026.1762d","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T19:34:05Z","timestamp":1787600045000},"page":"143-143","source":"Crossref","is-referenced-by-count":0,"title":["In Brief: Rextovy \u2014 Another OTC Naloxone Nasal Spray"],"prefix":"10.58347","volume":"68","member":"37151","published-online":{"date-parts":[[2026,8,31]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T19:34:07Z","timestamp":1787600047000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1762d"}},"subtitle":[],"editor":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":0,"journal-issue":{"issue":"1762","published-online":{"date-parts":[[2026,8,31]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2026.1762d","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]}}}